SCHEMBL707252

SCHEMBL707252

Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3ccn4ncnc(N)c34)cc2)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 12/20 0.83
AURKB Q96GD4 11/20 0.83
CDK1 P06493 5/20 0.70
STK3 Q13188 5/20 0.70
BLK P51451 5/20 0.70
MARK3 P27448 4/20 0.70
LCK P06239 4/20 0.70
KDR P35968 4/20 0.70
MARK2 Q7KZI7 4/20 0.70
FLT3 P36888 3/20 0.70
ROCK1 Q13464 3/20 0.70
NTRK2 Q16620 3/20 0.70
PDPK1 O15530 3/20 0.70
RPS6KA3 P51812 3/20 0.70
EGFR P00533 2/20 0.70
PIM1 P11309 2/20 0.70
JAK3 P52333 2/20 0.70
NTRK1 P04629 2/20 0.70
FYN P06241 2/20 0.70
LYN P07948 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL708728 0.92 AURKB (0.80) AURKAAURKBCDK1STK3BLK
SCHEMBL709079 0.91 AURKB (1.00) AURKAAURKBCDK1STK3BLK
SCHEMBL710921 0.87 AURKB (0.94) AURKAAURKBCDK1STK3BLK
SCHEMBL709714 0.86 AURKB (0.81) AURKAAURKBCDK1STK3BLK
SCHEMBL710637 0.85 AURKB (1.00) AURKAAURKBCDK1STK3BLK
SCHEMBL710479 0.85 AURKB (0.73) AURKAAURKBCDK1STK3BLK
SCHEMBL708688 0.85 AURKB (0.74) AURKAAURKBCDK1STK3BLK
SCHEMBL707878 0.84 AURKA (0.72) AURKAAURKBCDK1STK3BLK
SCHEMBL711553 0.83 AURKB (0.81) AURKAAURKBCDK1STK3BLK
SCHEMBL708227 0.83 AURKA (1.00) AURKAAURKBCDK1STK3BLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124759-B2 Inhibitors of protein kinases ABBOTT LABORATORIES (US) 2012-02-28 US claimed
EP-2297151-A1 INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-03-23 EP claimed
WO-2009136966-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-11-12 WO claimed
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-05-21 US claimed
US-8124759-B2 Inhibitors of protein kinases ABBOTT LABORATORIES (US) 2012-02-28 US disclosed
EP-2297151-A1 INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-03-23 EP disclosed
WO-2009136966-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-11-12 WO disclosed
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES AURKC, AURKB, PLK1 AURKA 4/4885AURKB 2/4885CDK1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.